Oral misoprostol for labor augmentation: a randomized controlled trial.

Area of Science:

• Obstetrics and Gynecology
• Reproductive Medicine
• Clinical Pharmacology

Background:

• Labor augmentation is frequently employed to improve labor progress.
• Oxytocin is the standard agent for labor augmentation.
• Oral misoprostol offers a potential alternative with different administration routes.

Purpose of the Study:

• To evaluate the efficacy and safety of oral misoprostol for labor augmentation.
• To compare oral misoprostol with intravenous oxytocin in a randomized controlled trial.

Main Methods:

• Randomized controlled trial comparing oral misoprostol (75 mcg) to intravenous oxytocin.
• Participants were women in spontaneous labor with cervical dilation of 4-8 cm requiring augmentation.
• Primary outcome: incidence of uterine tachysystole, hypertonus, or both. Secondary outcomes: labor duration, fetal heart rate, delivery mode, maternal/neonatal outcomes.

Main Results:

• Oral misoprostol significantly reduced the interval from admission to study drug initiation compared to oxytocin.
• No significant difference was observed in the time from augmentation initiation to delivery between groups.
• Women receiving oral misoprostol had a higher incidence of uterine hypertonus but not tachysystole.
• No differences in nonreassuring fetal heart rate, cesarean delivery rates, or maternal/neonatal outcomes were noted.

Conclusions:

• Oral misoprostol is an effective agent for labor augmentation.
• It offers a faster initiation of treatment compared to intravenous oxytocin.
• The increased incidence of uterine hypertonus with oral misoprostol requires careful monitoring but does not appear to increase adverse perinatal outcomes.